Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Merck
UBS
McKesson
Harvard Business School
Moodys
Federal Trade Commission
US Department of Justice
Dow

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LIDOCAINE HYDROCHLORIDE VISCOUS

« Back to Dashboard

Clinical Trials for Lidocaine Hydrochloride Viscous

Trial ID Title Status Sponsor Phase Summary
NCT00001524 Thalidomide to Treat Oral Lesions in HIV-Infected Patients Completed National Institute of Dental and Craniofacial Research (NIDCR) Phase 2 This study will test the effectiveness of topical thalidomide in healing mouth sores in HIV infected patients. Oral (PO) thalidomide heals these sores at a dose of 200 mg per day. However, PO thalidomide can cause drowsiness, skin rashes, allergic reactions, increased viral load, and even nerve damage that may not be reversible. This study will evaluate the efficacy of a topical formulation of thalidomide (placed directly on the surface of the sore) for the healing of these sores. Persons with HIV infection of acquired immunodeficiency of at least 18 years of age with one or more chronic, painful intraoral lesions may be eligible for this study. Subjects must be referred by a primary care physician who is managing their care, and must have HIV/AIDS status confirmed. Patients' HIV treatment regimen will not be altered and those receiving highly active therapy will not be excluded. Patients will be excluded if they are concurrently being treated for mucosal lesions (including topical or systemic steroids, viscous lidocaine, topical or systemic anti-fungals, or mouthwashes), or concurrent thalidomide therapy; receving chemotherapy or radiation therapy for neoplasms; using concurrent acute therapy for opportunistic infections; concurrent use of sedatives (such as CNS depressants or alcohol use); history of allergy to thalidomide; pre-existing peripheral neuropathy of grade II or higher; pregnant or lactating females or those not practicing contraception according to FDA guidelines for thalidomide.
NCT01087489 Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye Completed Bascom Palmer Eye Institute N/A Patient comfort during and after eye injections will be compared after two numbing (anesthetic) protocols, an eye preparation utilizing three cotton swabs soaked in 4% lidocaine drops versus a preparation using 3.5% lidocaine hydrochloride ophthalmic gel.
NCT01087489 Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye Completed University of Miami N/A Patient comfort during and after eye injections will be compared after two numbing (anesthetic) protocols, an eye preparation utilizing three cotton swabs soaked in 4% lidocaine drops versus a preparation using 3.5% lidocaine hydrochloride ophthalmic gel.
NCT01087489 Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye Completed Miami VA Healthcare System N/A Patient comfort during and after eye injections will be compared after two numbing (anesthetic) protocols, an eye preparation utilizing three cotton swabs soaked in 4% lidocaine drops versus a preparation using 3.5% lidocaine hydrochloride ophthalmic gel.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lidocaine Hydrochloride Viscous

Condition Name

Condition Name for Lidocaine Hydrochloride Viscous
Intervention Trials
Topical Anesthesia 1
Acquired Immunodeficiency Syndrome 1
Diabetic Macular Edema 1
Post-Dural Puncture Headache 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lidocaine Hydrochloride Viscous
Intervention Trials
Immunologic Deficiency Syndromes 1
Cataract 1
Esophageal Achalasia 1
HIV Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lidocaine Hydrochloride Viscous

Trials by Country

Trials by Country for Lidocaine Hydrochloride Viscous
Location Trials
United States 7
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lidocaine Hydrochloride Viscous
Location Trials
California 2
Florida 2
Utah 1
New York 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lidocaine Hydrochloride Viscous

Clinical Trial Phase

Clinical Trial Phase for Lidocaine Hydrochloride Viscous
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lidocaine Hydrochloride Viscous
Clinical Trial Phase Trials
Completed 5
Not yet recruiting 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lidocaine Hydrochloride Viscous

Sponsor Name

Sponsor Name for Lidocaine Hydrochloride Viscous
Sponsor Trials
Miami VA Healthcare System 1
Lawson Health Research Institute 1
University of Utah 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lidocaine Hydrochloride Viscous
Sponsor Trials
Other 15
NIH 1
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cipla
Chinese Patent Office
McKinsey
Healthtrust
UBS
Baxter
Fuji
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.